# US 2024/0254510 A1 · Methods for generating mechanically-responsive cells and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254510 A1
- Document ID: US20240254510A1
- Status: Published application
- Kind: A1
- Application number: 18/282,761
- Filed: 2022-03-21
- Published: 2024-08-01
- Earliest claimed: 2021-03-19
- Assignees: Washington University; Shriners Hospitals for Children
- Applicants: Washington University; Shriners Hospitals for Children
- Inventors: Farshid Guilak; Robert Nims; Lara Pferdehirt
- Web page: https://patentgrep.com/patent/US20240254510A1

## CPC

- A61L 27/38: {containing added animal cells (organs or tissue containing native cells A61L27/36)}
- C12N 15/86: Viral vectors
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C12N 5/0655: {Chondrocytes; Cartilage}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C07K 14/7155: {for interleukins [IL]}
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Among the various aspects of the present disclosure is the provision of compositions and methods of making genetically modified cells comprising a synthetic circuit that is responsive to a mechanical input to the cell and methods of use thereof. This disclosure uses mechanotransduction to provide gene-based delivery of biologic drugs at prescribed times, phases and frequencies. Once reprogrammed, the cells can be reimplanted in the body for this purpose.

## Claims

### Claim 1

A recombinant nucleic acid sequence comprising at least one transcriptional regulatory nucleic acid sequence of a mechanically-responsive gene operably linked to a nucleic acid sequence encoding a therapeutic biologic.

### Claim 2 (depends on 1)

The nucleic acid sequence of claim 1, wherein the at least one transcriptional regulatory nucleic acid sequence nucleic acid sequence is a promoter nucleic acid molecule of a mechanically-responsive gene.

### Claim 3 (depends on 1)

The nucleic acid sequence of claim 1, wherein the nucleic acid sequence further comprises a TATA box between the at least one transcriptional regulatory nucleic acid sequence of a mechanically-responsive gene and the nucleic acid sequence encoding a therapeutic biologic.

### Claim 4 (depends on 1)

A nucleic acid construct or vector comprising the nucleic acid sequence of claim 1.

### Claim 5 (depends on 4)

The vector of claim 4, wherein the vector is a viral vector.

### Claim 6 (depends on 5)

The viral vector of claim 5, wherein the viral vector is an adeno-associated viral vector or a lentiviral vector.

### Claim 7

(canceled)

### Claim 8 (depends on 2)

The nucleic acid claim 2, wherein
the promoter of a mechanically-responsive gene is selected from a NFKB promoter, a PTGS2 promoter, a PMEPA1 promoter, a FGF1 promoter, a SNORA70 promoter, a ADAMTS1 promoter, a IGSF9B promoter, a NR4A2 promoter, a NR4A1 promoter, a INHBA promoter, a CSRNP2 promoter, a PHLDA1 promoter, a GAN promoter, a SLC25A25 promoter, a SLC35E4 promoter, a CAND2 promoter, a SNCAIP promoter, a WNT9A promoter, a EGR1 promoter, a DUSP2 promoter, a SPRY4 promoter and combinations thereof.

### Claim 9 (depends on 1)

The nucleic acid claim 1, wherein the therapeutic biologic nucleic acid sequence encodes an anti-catabolic polypeptide, an anti-inflammatory polypeptide, a pro-anabolic polypeptide, a pro-regenerative polypeptide, an anti microbial polypeptide, an anti-pain polypeptide, a morphogen, a growth factor, an anti cancer nucleic acid or an anti-cancer polypeptides.

### Claim 10 (depends on 9)

The nucleic acid of claim 9, wherein the promoter is a PTGS2 promoter and the therapeutic biologic is an IL-1 receptor antagonist.

### Claim 11 (depends on 1)

A genetically modified cell comprising a heterologous nucleic acid sequence incorporated into its genome, wherein the heterologous nucleic acid sequence comprises the nucleic acid sequence of claim 1.

### Claim at position 12

-16. (canceled)

### Claim 17 (depends on 11)

The genetically modified cell of claim 11, wherein the cell expresses on its surface a mechanically sensitive ion channel.

### Claim 18 (depends on 17)

The genetically modified cell of claim 17, wherein the mechanically sensitive ion channel is from the transient receptor potential (TRP) family.

### Claim 19 (depends on 18)

The genetically modified cell of claim 18, wherein the mechanically sensitive ion channel is selected from TRPA1, TRP vanilloid 1 (TRPV1), and TRPV4.

### Claim 20 (depends on 19)

The genetically modified cell of claim 19, wherein the mechanically sensitive ion channel is TRPV4.

### Claim at position 17

-22. (canceled)

### Claim 23 (depends on 17)

The genetically modified cell of claim 17, wherein the mechanically sensitive ion channel is PIEZ01 and/or PIEZ02.

### Claim 24 (depends on 23)

The genetically modified cell of claim 23, wherein the promoter of a mechanically-responsive gene is selected from a ADAMTS1 promoter, a NR4A2 promoter, a NR4A1 promoter, a WNT9A promoter, a SPRY4 promoter, and combinations thereof.

### Claim 25 (depends on 11)

The genetically modified cell of claim 11, wherein the therapeutic biologic nucleic acid molecule encodes for one or more of IL-1 Ra, sTNFR1/2, IL-10 IL-4, a growth factor from the TGF superfamily, IGF, CTGF, FGF, PDGF, a kappa opioid ligand pro-peptide (e.g., prodynorphin), a mu/delta opioid ligand pro-peptide (e.g., proenkephalin), a delta/mu opioid ligand pro-peptide (proopiomelanocortin), an endocannabinoid ligand synthesis drivers TNF, IL-7, IL-15, IL-12, IL-2, IFN, NOS, PTGIS, Decorin, TGF-receptor, MMP, ALDH2, NR3C1 and any combination thereof.

### Claim at position 21

-27. (canceled)

### Claim 28 (depends on 11)

The genetically modified cell of claim 11, wherein the period, frequency, or phase of the therapeutic biologic expression is modulated through the at least one transcriptional regulatory nucleic acid molecule of a mechanically responsive gene or through use of combinations of the transcriptional regulatory nucleic acid molecules of a mechanically responsive gene.

### Claim at position 23

-31. (canceled)

### Claim 32 (depends on 11)

A method of treating a condition, disease or disorder in a subject in need thereof, the method comprising administering an effective amount of a composition comprising the genetically modified cell of claim 11.

### Claim 33 (depends on 32)

The method of claim 32, wherein the condition, disease or disorder is a chronic inflammatory disease, an acute inflammatory disease, a degenerative disease of any tissue or organ, chronic or acute pain, cancer, cardiovascular disease, osteoarthritis, cardiac hypertrophy, atherosclerosis, asthma, irritable bowel syndrome, muscle atrophy, angina, atrial fibrillation, hypertension, intimal hyperplasia, valve disease, scleroderma, achalasia, volvulus, diabetic nephropathy, glomerulosclerosis, cerebral edema, hydrocephalus, migraine, stroke, glaucoma, ankylosing spondylitis, carpal tunnel syndrome, chronic back pain, dupytre's contracture, osteoporosis, rheumatoid arthritis, collagenopathies, Musculo dystrophies, osteochondroplasias, polycystic kidney disease, ARDS, emphysema, pulmonary fibrosis, ventilator injury, pre-eclampsia, sexual dysfunction, or urinary incontinence.
